Citations

Clear

13 citation(s) found for "Todd, Michael".

Liver Point-of-Care Ultrasound (POCUS): Roadmap for training, credentialing, and implementation
Debes, Jose D., Gougol, Amir , Kim, W. Ray, Debes, José D. , Kono, Yuko , Dolinger, Michael Todd

Mayo Clinic

Hepatology Communications | August 11, 2026 | Volume: 10 | Issue: 9 | Pages: No page available

10.1097/hc9.0000000000001016 | PMID 42579772 Get It

Point-of-care ultrasound (POCUS) offers unique, real-time advantages for assessing liver disease, benefiting both health care providers and patients. It has been shown to enhance patient care and satisfaction across a variety of medical specialties. Although liver POCUS is practiced widely in many parts of the world, its use in the United States remains limited. Liver POCUS enables rapid assessment of specific hepatic conditions, including both vascular and parenchymal abnormalities, and can play a key role in timely management decision-making—such as guiding the use of diuretics or volume expanders. Once liver POCUS is established, ultrasonography-enabled procedures, such as procedure guidance and shear wave elastography, may be adopted and enrich the practice of hepatology in the future. This paper serves as a summary of the American Association for the Study of Liver Diseases' (AASLD) current position on liver POCUS, offering proposed imaging protocols, recommendations for training and credentialing, and practical guidelines for implementation in clinical settings.
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
Naing, Aung , Javle, Milind , Bajor, David L. , Shields, Anthony F. , Chawla, Sant P. , Safran, H., Powderly, John D. , D’Amato, Gina Z. , Meyer, Christian F. , Tang, Xiongwen , Yao, Sheng , Keegan, Patricia , Keegan, Patricia , Mahipal, Amit , Wang, Judy , Bauer, Todd Michael , Elias, Anthony , Davis, Elizabeth J.

Mayo Clinic

Journal of Immunotherapy and Precision Oncology | January 14, 2025 | Volume: 8 | Issue: 1 | Pages: 71-81

10.36401/jipo-24-8 | PMID 39816916 Get It

Introduction This was the first phase 1 study conducted in the United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion (part B), investigating the safety and preliminary efficacy of toripalimab (anti–programmed cell death-1 inhibitor) in patients with advanced malignancies. Methods Patients with advanced malignancies that progressed after treatment with at least one prior line of standard systemic therapy, including the patients with advanced/recurrent cholangiocarcinoma (CCA), received toripalimab 240 mg every 3 weeks in part B. The primary endpoint was safety assessment. Efficacy endpoints included objective response rate (ORR), disease control rate (DCR), duration of response (DoR), progression-free survival (PFS) as assessed by the investigators according to Response Evaluation Criteria in Solid Tumors (version 1.1) and overall survival (OS). Results In part B, 166 patients, including the 42 patients with CCA, were enrolled and received toripalimab. Among the 166 patients, treatment-emergent adverse events (TEAEs) of any grade occurred in 158 (95.2%) patients, and 97 (58.4%) patients experienced TEAEs of Grade 3 or greater. The most common TEAE was fatigue (42.2%). Seven (4.2%) patients experienced TEAEs with a fatal outcome, none of which were identified by investigators as related to toripalimab. Investigator-assessed immune-related adverse events (irAE) of Grade 3 or higher occurred in 7 (4.2%) patients. In the CCA cohort, with the median follow-up of 4.4 months, the ORR and DCR were 4.8% (95% CI: 0.58, 16.16) and 40.5% (95% CI: 25.63, 56.72), respectively; median DoR was 7.8 (range 4.4+ to 7.8) months; median PFS was 2.1 (95% CI: 1.91, 3.88) months; median OS was not estimable. Conclusions Toripalimab had manageable side effects in patients with refractory cholangiocarcinoma and exhibited preliminary evidence of anti-tumor activity. However, further information regarding biomarkers is needed. ClinicalTrials.gov ID: NCT03474640
SleepWell24, a Smartphone Application to Promote Adherence to Positive Airway Pressure Therapy: Feasibility and Acceptability in a Randomized Controlled Trial
Epstein, Dana R. , Krahn, Lois E., Todd, Michael , Park, John G. , Hoffmann, Coles M., Hasanaj, Kristina , Hollingshead, Kevin , Yu, Tsung-Yen, Krahn, Lois, St Louis, Erik K, Morgenthaler, Timothy I. , Petrov, Megan E. Ruiter , Louis, Erik K. St. , Buman, Matthew P.

Mayo Clinic

Behavioral Sleep Medicine | November 30, 2023 | Volume: 22 | Issue: 4 | Pages: 420-432

10.1080/15402002.2023.2289442 | PMID 38032115 Get It

Physicians’ Perspectives on HL7 Information Policy Sensitive Value Set: A Validation Study through Health Concept Categorization
Eluru, Maheswari , Mendoza, Daniel Hector, Wong, Audrey, Jafari, Mohammad, Todd, Michael , Bayless, Patricia , Chern, Darwyn , Eldredge, Christina , Franco-Fuquen, Pedro, García-Robledo, Juan Esteban , Gifford, Benjamin Grant, Hans, Rhea, Moreno-Cortes, Eider , Perumbeti, Ajay, Vargas-Cely, Fabio Samir , Garcia-Robledo, Juan Esteban , Moreno-Cortes, Eider F , Vargas-Cely, Fabio Samir , Fonseca, Rodrigo , Gifford, Benjamin Grant, Zhao, Lin , Grando, Adela , Hans, Rhea

Mayo Clinic

Healthcare | October 29, 2023 | Volume: 11 | Issue: 21 | Pages: 2845

10.3390/healthcare11212845 | PMID 37957990 Get It

The Health Level 7 (HL7) organization introduced the Information Sensitivity Policy Value Set with 45 sensitive data categories to facilitate the implementation of granular electronic consent technology. The goal is to allow patients to have control over the sharing of their sensitive medical records. This study represents the first attempt to explore physicians’ viewpoints on these categories. Twelve physicians participated in a survey, leading to revisions in 21 HL7 categories. They later classified 600 clinical data items through a second survey using the updated categories. Participants’ perspectives were documented, and data analysis included descriptive measures and heat maps. In the first survey, six participants suggested adding 19 new categories (e.g., personality disorder), and modifying 25 category definitions. Two new categories and sixteen revised category definitions were incorporated to support more patient-friendly content and inclusive language. Fifteen new category recommendations were addressed through a revision of category definitions (e.g., personality disorder described as a behavioral health condition). In the second survey, data categorizations led to recommendations for more categories from ten participants. Future revisions of the HL7 categories should incorporate physicians’ viewpoints, validate the categories using patient data or/and include patients’ perspectives, and develop patient-centric category specifications.
Physicians differ in their perceptions of sensitive medical records: Survey and interview study
Banerjee, Ipsha , Syed, Kazi, Potturu, Aishwarya S, Pragada, Venkata SVS, Sharma, Rishika S, Murcko, Anita , Chern, Darwyn , Todd, Michael , Aking, Padma, Al-Yaqoobi, Ali, Bayless, Patricia , Belmonte, Winona, Cuadra, Teresa, Dockins, Trudy, Eldredge, Christina , El‐Kareh, Robert , Gale, G. W., Gentile, Edward , Kalpas, Edward , Morris, Meghan D. , Mueller, Laurel, Piekut, Dorothy, Ross, Mindy K. , Sarris, John, Tharani, Shalini, Wallace, Mark C., Wallace, Mark, Grando, Maria Adela , Gale, Gregory, Morris, Meghan, Singh, Gagandeep, Wallace, Mark, Grando, Adela

Mayo Clinic

Health Informatics Journal | August 6, 2023 | Volume: 29 | Issue: 3 | Pages: No page available

10.1177/14604582231193519 | PMID 37544770 Get It

Physician categorizations of electronic health record (EHR) data (e.g., depression) into sensitive data categories (e.g., Mental Health) and their perspectives on the adequacy of the categories to classify medical record data were assessed. One thousand data items from patient EHR were classified by 20 physicians (10 psychiatrists paired with ten non-psychiatrist physicians) into data categories via a survey. Cluster-adjusted chi square tests and mixed models were used for analysis. 10 items were selected per each physician pair (100 items in total) for discussion during 20 follow-up interviews. Interviews were thematically analyzed. Survey item categorization yielded 500 (50.0%) agreements, 175 (17.5%) disagreements, 325 (32.5%) partial agreements. Categorization disagreements were associated with physician specialty and implied patient history. Non-psychiatrists selected significantly ( p = .016) more data categories than psychiatrists when classifying data items. The endorsement of Mental Health and Substance Use categories were significantly ( p = .001) related for both provider types. During thematic analysis, Encounter Diagnosis (100%), Problems (95%), Health Concerns (90%), and Medications (85%) were discussed the most when deciding the sensitivity of medical information. Most (90.0%) interview participants suggested adding additional data categories. Study findings may guide the evolution of digital patient-controlled granular data sharing technology and processes.
Relationship Functioning and Gut Microbiota Composition among Older Adult Couples
Cheng, Qiwen , Krajmalnik‐Brown, Rosa , DiBaise, John K. , Maldonado, Juan , Guest, M. Aaron , Todd, Michael , Langer, Shelby L.

Mayo Clinic

International Journal of Environmental Research and Public Health | April 10, 2023 | Volume: 20 | Issue: 8 | Pages: 5435

10.3390/ijerph20085435 | PMID 37107717 Get It

An emerging area of research extends work on couple functioning and physical health to gut health, a critical marker of general health and known to diminish with age. As a foray into this area, we conducted a pilot study to (1) determine the feasibility of remote data collection, including a fecal sample, from older adult couples, (2) examine within-couple concordance in gut microbiota composition, and (3) examine associations between relationship functioning and gut microbiota composition. Couples (N = 30) were recruited from the community. The participants’ demographic characteristics were as follows: M (SD) age = 66.6 (4.8), 53% female, 92% White, and 2% Hispanic. Two of the couples were same-sex. All 60 participants completed self-report measures and supplied a fecal sample for microbiome analysis. Microbial DNA was extracted from the samples, and the 16S rRNA gene V4 region was amplified and sequenced. The results indicated that individuals shared more similar gut microbial composition with their partners than with others in the sample, p < 0.0001. In addition, individuals with better relationship quality (greater relationship satisfaction and intimacy and less avoidant communication) had greater microbial diversity, p < 0.05, a sign of healthier gut microbiota. Further research with a larger and more diverse sample is warranted to elucidate mechanisms.
Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors
Blank, Christian U. , Wong, Deborah J. , Ho, Thai H. , Lee, Carrie B. , Bene‐Tchaleu, Fabiola, Zhu, Jing, Zhang, Xiaosong, Cha, Edward , Sznol, Mario , Ho, Thai , Bauer, Todd Michael , Zhang, Xiaosong

Mayo Clinic

Current Oncology | December 21, 2021 | Volume: 28 | Issue: 6 | Pages: 5466-5479

10.3390/curroncol28060455 | PMID 34940094 Get It

This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-α, with/without vascular endothelial growth factor inhibitor, bevacizumab, in renal cell carcinoma (RCC) and other solid tumors. Arm B predominantly recruited patients with previously treated RCC or melanoma to receive atezolizumab plus interferon α-2b. Arm C investigated atezolizumab plus polyethylene glycol (PEG)-interferon α-2a in previously treated RCC. Arm D evaluated atezolizumab plus PEG-interferon α-2a and bevacizumab. Primary objectives were safety and tolerability; secondary objectives included clinical activity. Combination therapy was well tolerated, with safety profiles consistent with known risks of individual agents. The most frequent treatment-related toxicities were fatigue, chills, and pyrexia. The objective response rate (ORR) in arm B was 20.0% overall and 17.8% in patients with previously treated checkpoint inhibitor–naive RCC (n = 45). No responses were reported in arm C. The highest ORR in arm D was 46.7% in patients with treatment-naive RCC (n = 15). Data showed preliminary clinical activity and acceptable tolerability of atezolizumab plus interferon α-2b in patients with previously treated checkpoint inhibitor–naive RCC and of atezolizumab plus PEG-interferon α-2a and bevacizumab in patients with treatment-naive RCC.
High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).
Nordstrom, Jeffrey L., Muth, John, Erskine, Courtney L. , Sanders, Catherine , Yusko, Erik, Emerson, Ryan , Lee, Min-Jung , Trepel, Jane B. , Bang, Yung‐Jue, Burris, Howard A. , Baughman, Jan, Rock, Edwin P. , Moore, Paul A. , Bonvini, Ezio , Knutson, Keith L. , Lee, Sunmin , Im, Seock‐Ah , Bang, Yung‐Jue , Giaccone, Giuseppe , Bauer, Todd Michael , Knutson, Keith L.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2019 | Volume: 37 | Issue: 15_suppl | Pages: 1030-1030

10.1200/jco.2019.37.15_suppl.1030 Get It

1030 Background: Previous studies have shown that 44-71% of trastuzumab (T)-treated pts develop HER2-specific immunity (Clin Cancer Res 2007, 13:5133; Cancer Res 2016, 76:3702; Breast Cancer Res 2018, 20:52). M is an Fc-engineered mAb that shares similar HER2 binding and antiproliferative activity as T. The Fc region of M has been engineered for increased affinity to the activating FcγRIIIA (CD16A) and lower binding to the inhibitory FcγRIIB (CD32B), attributes that may enhance the mAb’s immune function, such as antigen presentation. Methods: HER2+ cancer pts who progressed on prior therapy received M (0.1-6 mg/kg QW for 3 of every 4 weeks [N = 34]; or 10-18 mg/kg Q3W [N = 32]) in phase 1 trial NCT01148849. PBMC and plasma were collected pre-dose and 50 days post-dose for 46 pts and > 4 years for 3 pts on long-term treatment. Response to HER2 or control antigens (Ag) was assessed by IFNγ ELISpot and antibody (Ab) ELISA. In 14 pts, T-cell antigen receptor (TCR) repertoire was assessed by immunosequencing. Results: Following M treatment, mean frequencies of IFNγ-producing T cells specific for intra- or extracellular fragments of HER2 increased by 2.5 to 6-fold (p < 0.0027, paired t test). Most (95%) of subjects responded to ≥2 of 6 (median = 5) HER2 Ag. Mean HER2-specific Ab concentration increased by 19-54% (p < 0.0001), with all subjects responding to ≥2 (median = 5) of the 6 Ag. A small 1.6-fold increase in IFNγ response to control CMV/EBV/Flu (but not tetanus or cyclin D1) peptides was observed; no increase in Ab response to control Ag was noted. Subsets of HER2-specific T-cell and Ab responses persisted during long-term treatment. Median TCR clonality increased by 54% (p = 0.003), with an average of 125 unique clones expanding, while overall TCR diversity remained unchanged (p = 0.19). Conclusions: Treatment of HER2+ cancer with M was associated with enhanced HER2-specific T-cell and Ab responses together with increased TCR clonality, indicative of a more focused T-cell repertoire. The high frequency of HER2-specific immunity in M-treated patients ( > 95%) is consistent with its enhanced Fc region contributing to linkage of innate and adaptive immune responses.
Consensus Statement on Perioperative Use of Neuromuscular Monitoring
Naguib, Mohamed , Brull, Sorin J. , Kopman, Aaron F., Hunter, Jennifer M. , Arkes, Hal R. , Elstein, Arthur S., Todd, Michael M. , Johnson, Ken B. , Fülesdi, Béla , Brull, Sorin J

Mayo Clinic

Anesthesia & Analgesia | December 1, 2017 | Volume: 127 | Issue: 1 | Pages: 71-80

10.1213/ane.0000000000002670 | PMID 29200077 Get It

A panel of clinician scientists with expertise in neuromuscular blockade (NMB) monitoring was convened with a charge to prepare a consensus statement on indications for and proper use of such monitors. The aims of this article are to: (a) provide the rationale and scientific basis for the use of quantitative NMB monitoring; (b) offer a set of recommendations for quantitative NMB monitoring standards; (c) specify educational goals; and (d) propose training recommendations to ensure proper neuromuscular monitoring and management. The panel believes that whenever a neuromuscular blocker is administered, neuromuscular function must be monitored by observing the evoked muscular response to peripheral nerve stimulation. Ideally, this should be done at the hand muscles (not the facial muscles) with a quantitative (objective) monitor. Objective monitoring (documentation of train-of-four ratio ≥0.90) is the only method of assuring that satisfactory recovery of neuromuscular function has taken place. The panel also recommends that subjective evaluation of the responses to train-of-four stimulation (when using a peripheral nerve stimulator) or clinical tests of recovery from NMB (such as the 5-second head lift) should be abandoned in favor of objective monitoring. During an interim period for establishing these recommendations, if only a peripheral nerve stimulator is available, its use should be mandatory in any patient receiving a neuromuscular blocking drug. The panel acknowledges that publishing this statement per se will not result in its spontaneous acceptance, adherence to its recommendations, or change in routine practice. Implementation of objective monitoring will likely require professional societies and anesthesia department leadership to champion its use to change anesthesia practitioner behavior.
Michael M. Todd, M.D., Recipient of the 2016 Excellence in Research Award
Warner, David S. , Lanier, William L.

Mayo Clinic

Anesthesiology | August 9, 2016 | Volume: 125 | Issue: 4 | Pages: 641-644

10.1097/aln.0000000000001291 Get It